Itruvone

Itruvone (PH10; pregn-4-en-20-yn-3-one; CAS 21321-89-1) is a synthetic neuroactive steroid of the pregnane class and the second clinical-stage pherine (vomeropherine) molecule, under development by VistaGen Therapeutics as an intranasal nasal spray for the treatment of major depressive disorder (MDD). The compound is structurally characterized by a 17-alpha-ethynyl substituent on the pregnane steroid nucleus and a 3-keto-4-ene A-ring motif, yielding an odorless crystalline material with a molecular weight of 296.45 g/mol and the molecular formula C21H28O. Itruvone is pharmacologically distinguished from all currently approved antidepressants, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and the rapid-onset agents esketamine and brexanolone, by a proposed mechanism of action that does not require systemic absorption or direct activity on neuronal receptors in the brain. Instead, the compound is administered at microgram-level intranasal doses (3.2 to 6.4 micrograms per day) and is designed to engage and activate chemosensory receptor neurons in the nasal epithelium, which in turn activate olfactory bulb projections to the amygdala, hypothalamus, and prefrontal cortex through olfactory-amygdala neural circuits believed to modulate the activity of the limbic-hypothalamic sympathetic nervous system and increase the release of catecholamines from midbrain nuclei.

Preclinical tissue distribution studies using radiolabeled [14C]PH10 in rats demonstrated that a single intranasal administration was essentially undetectable in the brain and most other tissues, including blood and plasma, supporting the hypothesis that therapeutic activity occurs through peripheral chemosensory signaling rather than through systemic drug exposure. Preclinical electrophysiology studies further demonstrated that itruvone's mechanism does not involve direct activation of GABA-A receptors in the brain, differentiating it from benzodiazepines and from the neurosteroid antidepressant brexanolone (allopregnanolone).

The clinical evidence base comprises a positive Phase 2A randomized, double-blind, placebo-controlled trial conducted in Mexico in 30 patients with MDD, in which daily self-administered intranasal itruvone at 6.4 micrograms produced a mean 17-item Hamilton Depression Rating Scale (HAM-D-17) score reduction of 10.1 points after one week (compared to 4.2 points for placebo, p = 0.03) and 17.8 points after eight weeks, with the drug well tolerated and minimal side effects reported; a successful U.S. Phase 1 safety and tolerability study in healthy adult subjects completed in 2023 with no serious adverse events, no discontinuations due to adverse events, and only two mild adverse events (fatigue and headache in the same subject); and supportive prior clinical studies. The U.S. Food and Drug Administration has granted Fast Track designation for the development of itruvone as a potential treatment for MDD.

This monograph reviews the chemistry, structural classification, and synthesis of itruvone; the pherine pharmacology and nasal chemosensory receptor mechanism; the available pharmacokinetic and tissue distribution data; preclinical pharmacology including electrophysiology and tissue distribution studies; the clinical evidence base across Phase 1 and Phase 2A trials; sourcing and quality verification for research-grade material; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five alternative antidepressant approaches against itruvone on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by any regulatory authority for any indication. It is an investigational drug in clinical development; investigators should obtain appropriate regulatory authorization before any human research application.